XV638

XV638 is an experimental small molecule HIV protease inhibitor belonging to the class of diazepanones and benzamides. It is a potent inhibitor of HIV‑1 protease and has demonstrated efficacy against both wild-type and drug-resistant variants of the enzyme. Structural studies show that its increased potency over earlier cyclic urea-based inhibitors is due to enhanced P2-S2 interactions within the protease active site. These interactions provide more van der Waals contacts and additional hydrogen bonds compared to first-generation inhibitors. As a result, XV638 can inhibit a broad panel of drug-resistant HIV‑1 proteases by compensating for resistance-associated mutations in the S1 subsite[2][5]. The compound has not been approved for clinical use.

Other names

183854-11-7(4R-(4alpha,5alpha,6beta,7beta))-3,3'-((Tetrahydro-5,6-dihydroxy-2-oxo-4,7-bis(phenylmethyl)-1H-1,3-diazepine-1,3(2H)-diyl)-bis(methylene))bis(N-2-thiazolylbenzamide)